Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued to investors on Tuesday. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Performance

Shares of BCLI stock opened at $1.16 on Tuesday. The firm’s 50-day moving average is $1.19 and its 200-day moving average is $1.58. The stock has a market cap of $7.57 million, a price-to-earnings ratio of -0.24 and a beta of 0.35. Brainstorm Cell Therapeutics has a 52-week low of $0.72 and a 52-week high of $10.05.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its earnings results on Thursday, May 15th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.07). Sell-side analysts predict that Brainstorm Cell Therapeutics will post -3.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC purchased a new stake in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 690,666 shares of the biotechnology company’s stock, valued at approximately $870,000. Armistice Capital LLC owned about 10.59% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities and Exchange Commission. 14.33% of the stock is owned by institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.